— Main Menu —
Recent News About Inspirion Delivery Sciences, a subsidiary of Inspirion Delivery Technologies
View MorphaBond™ ER Full Prescribing Information
View RoxyBond™ Full Prescribing Information
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.
May 30, 2017
Inspirion Delivery Sciences Receives FDA Approval for RoxyBond™ (oxycodone hydrochloride) tablets CII, the First and Only Immediate Release Opioid Analgesic with Abuse-Deterrent Label Claims.
April 26, 2017
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond™ Formulated with SentryBond™ Abuse-Deterrent Technology
. October 25, 2016
Inspirion Delivery Technologies Receives FDA Approval for MorphaBond™ (morphine sulfate) extended-release tablets CII, an Opioid Analgesic Formulated with Abuse-Deterrent Properties
. October 05, 2015
Inspirion Delivery Technologies Announces FDA Acceptance of MorphaBond™ ER (morphine sulfate extended-release) New Drug Application; Its Investigational Abuse-Deterrent, Extended-Release Opioid.
February 09, 2015